Offering state-of-the-art genetic testing to patients with the blood cancer myeloma would help doctors spot those with the most aggressive forms of the disease so that their cancer can be targeted ...

The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or ...

To Measure is to Predict; Characterization of Response to Therapy in Plasma Cell Disorders ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight infection by making antibodies.

Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight infection by making antibodies. Multiple myeloma starts in the plasma ...

Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ages.